pentoxifylline has been researched along with Cirrhosis in 53 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a randomized clinical trial to determine whether the combination of pentoxifylline (PTX) and vitamin E given for 6 months after breast/chest wall irradiation effectively prevents radiation-induced fibrosis (RIF)." | 9.17 | Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. ( Bhatia, S; Bodeker, K; Buatti, J; Button, AM; Jacobson, G; Smith, BJ, 2013) |
| " A number of studies testing alpha-tocopherol (vitamin E) and pentoxifylline suggest evidence of clinical regression of superficial radiation-induced fibrosis but there is only very limited evidence from randomised trials." | 9.11 | Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. ( Cornes, P; Earl, J; Gothard, L; Hall, E; MacLaren, J; Mortimer, P; Peacock, J; Peckitt, C; Woods, M; Yarnold, J, 2004) |
| "In an open label drug trial, we studied the effects of pentoxifylline (400 mg orally tid for 8 weeks) on 30 patients who displayed late, radiation-induced fibrosis at 1 to 29 years posttreatment (40 to 84 Gy)." | 9.11 | Pentoxifylline in the treatment of radiation-induced fibrosis. ( Abraham, EH; Altemus, RM; Augustine, E; Coleman, N; Cornelison, TL; Ding, I; Gerber, LH; Hicks, JE; Huser, AK; Naydich, BG; Okunieff, P; Smith, JJ, 2004) |
| "Literature retrieval was performed through MEDLINE (1966-March 2004) using the terms vitamin E, alpha-tocopherol, pentoxifylline, radiation-induced fibrosis, and radiation injury." | 8.82 | Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. ( Chiao, TB; Lee, AJ, 2005) |
| "The data indicate a beneficial therapeutic effect of pentoxifylline and vitamin E on radiation-induced fibrosis." | 8.79 | [The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report]. ( Gottlöber, P; Korting, HC; Krähn, G; Peter, RU; Stock, W, 1996) |
| "To investigate the preventive effects of systemic honokiol and pentoxifylline treatments on epidural fibrosis (EF) in the experimental laminectomy model." | 8.02 | The Preventive Effect of Systemic Honokiol and Systemic Pentoxifylline on Epidural Fibrosis. ( Kurutas, EB; Secinti, IE; Secinti, KD, 2021) |
| "This study was designed to identify the effect of pentoxifylline on trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats." | 7.85 | Pentoxifylline attenuates mucosal damage in an experimental model of rat colitis by modulating tissue biomarkers of inflammation, oxidative stress, and fibrosis. ( Arhan, M; Ekinci, Ö; Erdal, H; G Dumlu, Ş; Gül Utku, Ö; Ibiş, M; Karatay, E; Önal, İK; Yilmaz Demirtaş, C, 2017) |
| "The aim of this experimental study was to investigate the effectiveness of intramuscular pentoxifylline in the prevention of postoperative fibrosis." | 7.83 | Pentoxifylline Inhibits Epidural Fibrosis in Post-Laminectomy Rats. ( Antar, V; Erdogan, H; Karaoglan, A; Kelten, B; Kutnu, M; Orki, T; Sanel, S; Tuncdemir, M, 2016) |
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 7.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Pentoxifylline (PTX) has been shown to inhibit renal inflammation in a rat model of crescentic glomerulonephritis." | 7.75 | Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. ( Chen, YM; Lan, HY; Lan, XR; Ng, YY; Tsai, TJ; Yang, WC, 2009) |
| " Oral feeding of yellow phosphorus to pigs reproducibly results in fibrosis after 8 weeks of feeding, extensive fibrosis after 12 weeks and cirrhosis after 16 weeks of yellow phosphorus." | 7.69 | Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. ( Neumeister, M; Peterson, TC, 1996) |
| "Radiation-induced fibrosis is a side effect of radiation therapy and may occur in up to 13% of the cases in patients (Radiother Oncol, 2009;90:80), fortunately usually is modest/localized and not associated with marked symptoms." | 6.58 | Pentoxifylline and vitamin E for treatment or prevention of radiation-induced fibrosis in patients with breast cancer. ( Jones, EL; Kaidar-Person, O; Marks, LB, 2018) |
| "Fibrosis is a potentially debilitating disease with high morbidity rates." | 6.55 | Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. ( Koh, RY; Lee, SY; Siang, R; Wen, WX, 2017) |
| "Pentoxifylline and M-1 treatment significantly attenuated colon damage and inflammation in TNBS-colitis (P<0." | 5.37 | The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis. ( Peterson, MR; Peterson, TC; Raoul, JM, 2011) |
| "Compared with the control group, PTX treatment reduced fibrosis scores at d 7 and d 14 (P<0." | 5.35 | Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression. ( Hou, FF; Zheng, FL; Zhou, QG, 2009) |
| "Pentoxifylline (PTX) is a potent inhibitor of connective tissue growth factor (CTGF), but its underlying mechanism is poorly understood." | 5.33 | Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. ( Chen, RH; Chen, YM; Chiang, WC; Lai, CF; Lin, SL; Tsai, TJ; Wu, KD, 2005) |
| "Fibrosis is a common pathological feature observed in muscle from patients with Duchenne muscular dystrophy and in mdx diaphragm." | 5.33 | Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle. ( Gosselin, LE; Williams, JE, 2006) |
| " Our results support the hypothesis that the increase in NO and/or cGMP/cAMP levels by long-term administration of nitrergic agents or inhibitors of PDE, may be effective in reversing the fibrosis of PD, and more speculatively, other fibrotic conditions." | 5.32 | L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. ( Ferrini, MG; Gonzalez-Cadavid, NF; Qian, A; Rajfer, J; Valente, EG; Vernet, D, 2003) |
| " One experimental group of 5 pigs was dosed orally for 26 weeks starting 26 weeks after irradiation with 1600 mg/120 kg body weight of pentoxifylline (PTX) included in the reconstituted food during its fabrication, and another group of 5 was dosed orally for the same period with a daily dose of 1600 mg/120 kg body weight of PTX combined with 2000 IU/120 kg body weight of alpha-tocopherol." | 5.30 | Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study. ( Delanian, S; Lefaix, JL; Leplat, JJ; Martin, M; Tricaud, Y; Vozenin, MC, 1999) |
| "To conduct a randomized clinical trial to determine whether the combination of pentoxifylline (PTX) and vitamin E given for 6 months after breast/chest wall irradiation effectively prevents radiation-induced fibrosis (RIF)." | 5.17 | Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. ( Bhatia, S; Bodeker, K; Buatti, J; Button, AM; Jacobson, G; Smith, BJ, 2013) |
| " A number of studies testing alpha-tocopherol (vitamin E) and pentoxifylline suggest evidence of clinical regression of superficial radiation-induced fibrosis but there is only very limited evidence from randomised trials." | 5.11 | Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. ( Cornes, P; Earl, J; Gothard, L; Hall, E; MacLaren, J; Mortimer, P; Peacock, J; Peckitt, C; Woods, M; Yarnold, J, 2004) |
| "In an open label drug trial, we studied the effects of pentoxifylline (400 mg orally tid for 8 weeks) on 30 patients who displayed late, radiation-induced fibrosis at 1 to 29 years posttreatment (40 to 84 Gy)." | 5.11 | Pentoxifylline in the treatment of radiation-induced fibrosis. ( Abraham, EH; Altemus, RM; Augustine, E; Coleman, N; Cornelison, TL; Ding, I; Gerber, LH; Hicks, JE; Huser, AK; Naydich, BG; Okunieff, P; Smith, JJ, 2004) |
| "To review the conservative and surgical management options of osteoradionecrosis, in particular, highlighting the recent the use of anti-radiation fibrosis drugs (pentoxifylline, tocopherol and clodronate)." | 4.91 | The management of osteoradionecrosis of the jaws--a review. ( Ekanayake, K; Omer, O; Polyzois, I; Rice, N; Stassen, LF, 2015) |
| "Literature retrieval was performed through MEDLINE (1966-March 2004) using the terms vitamin E, alpha-tocopherol, pentoxifylline, radiation-induced fibrosis, and radiation injury." | 4.82 | Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. ( Chiao, TB; Lee, AJ, 2005) |
| "The data indicate a beneficial therapeutic effect of pentoxifylline and vitamin E on radiation-induced fibrosis." | 4.79 | [The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report]. ( Gottlöber, P; Korting, HC; Krähn, G; Peter, RU; Stock, W, 1996) |
| "To investigate the preventive effects of systemic honokiol and pentoxifylline treatments on epidural fibrosis (EF) in the experimental laminectomy model." | 4.02 | The Preventive Effect of Systemic Honokiol and Systemic Pentoxifylline on Epidural Fibrosis. ( Kurutas, EB; Secinti, IE; Secinti, KD, 2021) |
| "A combination of pentoxifylline (PTX) and tocopherol (TP) is believed to reduce chronic fibrosis and induce bone healing in osteoradionecrosis (ORN) of the mandible, but evidence of its therapeutic effectiveness for cortical bone is lacking." | 3.91 | Effects of pentoxifylline and tocopherol on a rat-irradiated jaw model using micro-CT cortical bone analysis. ( Eo, MY; Kim, SM; Lee, JH; Myoung, H; Nguyen, TTH; Seo, MH, 2019) |
| "This study was designed to identify the effect of pentoxifylline on trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats." | 3.85 | Pentoxifylline attenuates mucosal damage in an experimental model of rat colitis by modulating tissue biomarkers of inflammation, oxidative stress, and fibrosis. ( Arhan, M; Ekinci, Ö; Erdal, H; G Dumlu, Ş; Gül Utku, Ö; Ibiş, M; Karatay, E; Önal, İK; Yilmaz Demirtaş, C, 2017) |
| "The aim of this experimental study was to investigate the effectiveness of intramuscular pentoxifylline in the prevention of postoperative fibrosis." | 3.83 | Pentoxifylline Inhibits Epidural Fibrosis in Post-Laminectomy Rats. ( Antar, V; Erdogan, H; Karaoglan, A; Kelten, B; Kutnu, M; Orki, T; Sanel, S; Tuncdemir, M, 2016) |
| "Pentoxifylline (PTX) has been shown to inhibit renal inflammation in a rat model of crescentic glomerulonephritis." | 3.75 | Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. ( Chen, YM; Lan, HY; Lan, XR; Ng, YY; Tsai, TJ; Yang, WC, 2009) |
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 3.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "To investigate whether the application of vitamin E with or without pentoxifylline could modify the development of radiation-induced pulmonary fibrosis." | 3.74 | Vitamin E protects against the development of radiation-induced pulmonary fibrosis in rats. ( Altug, T; Arbak, S; Bese, NS; Munzuroglu, F; Ober, A; Sut, N; Uslu, B; Yesiladali, G, 2007) |
| " The present study compares the effects of the cGMP production-increasing soluble guanylate cyclase (sGC) stimulator BAY 41-2272 with those of the cGMP degradation-limiting phosphodiesterase inhibitor pentoxifylline (PTX) in a progressive model of renal fibrosis." | 3.73 | Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2006) |
| "Previous studies have reported that pentoxifylline, a phosphodiesterase inhibitor, attenuates experimental mesangial proliferative glomerulonephritis." | 3.71 | Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. ( Chen, YM; Chiang, WC; Chien, CT; Lin, SL; Tsai, CC; Tsai, TJ, 2002) |
| "7%), fibrosis was significantly reduced in the pentoxifylline- and ciprofloxacin-treated groups (4." | 3.70 | Effect of preoperative interventions on outcome following liver resection in a rat model of cirrhosis. ( Gong, Y; Johnson, J; Kneteman, N; Minuk, GY; Moser, M; Zhang, M, 2000) |
| " Oral feeding of yellow phosphorus to pigs reproducibly results in fibrosis after 8 weeks of feeding, extensive fibrosis after 12 weeks and cirrhosis after 16 weeks of yellow phosphorus." | 3.69 | Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism. ( Neumeister, M; Peterson, TC, 1996) |
| "Radiation-induced fibrosis is a side effect of radiation therapy and may occur in up to 13% of the cases in patients (Radiother Oncol, 2009;90:80), fortunately usually is modest/localized and not associated with marked symptoms." | 2.58 | Pentoxifylline and vitamin E for treatment or prevention of radiation-induced fibrosis in patients with breast cancer. ( Jones, EL; Kaidar-Person, O; Marks, LB, 2018) |
| "Fibrosis is a potentially debilitating disease with high morbidity rates." | 2.55 | Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. ( Koh, RY; Lee, SY; Siang, R; Wen, WX, 2017) |
| "In the future, these treatments of fibrosis and necrosis should include targeted drugs (such as growth factors) to take organ specificities into account." | 2.44 | Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. ( Delanian, S; Lefaix, JL, 2007) |
| "Pentoxifylline-vitamin E has proven effective and safe in clinical trials in the treatment of fibrosis, while the molecular mechanism of its activity is yet unexplored." | 1.38 | Radiation-induced enteropathy: molecular basis of pentoxifylline-vitamin E anti-fibrotic effect involved TGF-β1 cascade inhibition. ( Delanian, S; Gilbert-Sirieix, M; Hamama, S; Vozenin, MC, 2012) |
| "Pentoxifylline and M-1 treatment significantly attenuated colon damage and inflammation in TNBS-colitis (P<0." | 1.37 | The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis. ( Peterson, MR; Peterson, TC; Raoul, JM, 2011) |
| "Compared with the control group, PTX treatment reduced fibrosis scores at d 7 and d 14 (P<0." | 1.35 | Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression. ( Hou, FF; Zheng, FL; Zhou, QG, 2009) |
| "Fibrosis is a common pathological feature observed in muscle from patients with Duchenne muscular dystrophy and in mdx diaphragm." | 1.33 | Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle. ( Gosselin, LE; Williams, JE, 2006) |
| "Pentoxifylline (PTX) is a potent inhibitor of connective tissue growth factor (CTGF), but its underlying mechanism is poorly understood." | 1.33 | Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. ( Chen, RH; Chen, YM; Chiang, WC; Lai, CF; Lin, SL; Tsai, TJ; Wu, KD, 2005) |
| " Our results support the hypothesis that the increase in NO and/or cGMP/cAMP levels by long-term administration of nitrergic agents or inhibitors of PDE, may be effective in reversing the fibrosis of PD, and more speculatively, other fibrotic conditions." | 1.32 | L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. ( Ferrini, MG; Gonzalez-Cadavid, NF; Qian, A; Rajfer, J; Valente, EG; Vernet, D, 2003) |
| "Pentoxifylline is a methylxanthine derivative that produces dose-related hemorrheologic effects, lower blood viscosity, improved erythrocyte flexibility, and increased tissue oxygen levels." | 1.30 | Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. ( Futran, ND; Gwede, C; Trotti, A, 1997) |
| " One experimental group of 5 pigs was dosed orally for 26 weeks starting 26 weeks after irradiation with 1600 mg/120 kg body weight of pentoxifylline (PTX) included in the reconstituted food during its fabrication, and another group of 5 was dosed orally for the same period with a daily dose of 1600 mg/120 kg body weight of PTX combined with 2000 IU/120 kg body weight of alpha-tocopherol." | 1.30 | Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study. ( Delanian, S; Lefaix, JL; Leplat, JJ; Martin, M; Tricaud, Y; Vozenin, MC, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (11.32) | 18.2507 |
| 2000's | 24 (45.28) | 29.6817 |
| 2010's | 18 (33.96) | 24.3611 |
| 2020's | 5 (9.43) | 2.80 |
| Authors | Studies |
|---|---|
| Binatti, E | 1 |
| Zoccatelli, G | 1 |
| Zanoni, F | 1 |
| Donà, G | 1 |
| Mainente, F | 1 |
| Chignola, R | 1 |
| Secinti, KD | 1 |
| Secinti, IE | 1 |
| Kurutas, EB | 1 |
| Seo, MH | 2 |
| Kim, DW | 1 |
| Kim, YS | 1 |
| Lee, SK | 1 |
| Silva Grijó Farani, P | 1 |
| Iandra da Silva Ferreira, B | 1 |
| Begum, K | 1 |
| Vilar-Pereira, G | 1 |
| Pereira, IR | 1 |
| Fernández-Figueroa, EA | 1 |
| Cardenas-Ovando, RA | 1 |
| Almeida, IC | 1 |
| Roy, S | 1 |
| Lannes-Vieira, J | 1 |
| Moreira, OC | 1 |
| Nguyen, TTH | 1 |
| Eo, MY | 1 |
| Myoung, H | 1 |
| Kim, SM | 1 |
| Lee, JH | 1 |
| Eslahi, A | 1 |
| Shirazi, M | 1 |
| Khoshnood, O | 1 |
| Noorafshan, A | 1 |
| Karbalay-Doust, S | 1 |
| Wen, WX | 1 |
| Lee, SY | 1 |
| Siang, R | 1 |
| Koh, RY | 1 |
| Kumar, D | 1 |
| Yalamanchali, S | 1 |
| New, J | 1 |
| Parsel, S | 1 |
| New, N | 1 |
| Holcomb, A | 1 |
| Gunewardena, S | 1 |
| Tawfik, O | 1 |
| Lominska, C | 1 |
| Kimler, BF | 1 |
| Anant, S | 1 |
| Kakarala, K | 1 |
| Tsue, T | 1 |
| Shnayder, Y | 1 |
| Sykes, K | 1 |
| Padhye, S | 1 |
| Thomas, SM | 1 |
| Ionică, FE | 1 |
| Mogoantă, L | 1 |
| Negreş, S | 1 |
| Bejenaru, LE | 1 |
| Cristea, OM | 1 |
| Badea, O | 1 |
| Bejenaru, C | 1 |
| Kaidar-Person, O | 1 |
| Marks, LB | 1 |
| Jones, EL | 1 |
| Yang, F | 1 |
| Chen, E | 1 |
| Yang, Y | 1 |
| Han, F | 1 |
| Han, S | 1 |
| Wu, G | 1 |
| Zhang, M | 2 |
| Zhang, J | 1 |
| Han, J | 1 |
| Su, L | 1 |
| Hu, D | 1 |
| Hamama, S | 2 |
| Noman, MZ | 1 |
| Gervaz, P | 1 |
| Delanian, S | 7 |
| Vozenin, MC | 3 |
| Mohamed, DI | 1 |
| Elmelegy, AA | 1 |
| El-Aziz, LF | 1 |
| Abdel Kawy, HS | 1 |
| AbdEl-Samad, AA | 1 |
| El-Kharashi, OA | 1 |
| Rice, N | 1 |
| Polyzois, I | 1 |
| Ekanayake, K | 1 |
| Omer, O | 1 |
| Stassen, LF | 1 |
| Lee, R | 1 |
| MacKinnon, CA | 1 |
| Aburn, N | 1 |
| Tan, ST | 1 |
| Zhang, X | 1 |
| Meng, F | 1 |
| Song, J | 1 |
| Zhang, L | 1 |
| Wang, J | 1 |
| Li, D | 1 |
| Li, L | 1 |
| Dong, P | 1 |
| Yang, B | 1 |
| Chen, Y | 1 |
| Kelten, B | 1 |
| Erdogan, H | 1 |
| Antar, V | 1 |
| Sanel, S | 1 |
| Tuncdemir, M | 1 |
| Kutnu, M | 1 |
| Karaoglan, A | 1 |
| Orki, T | 1 |
| Patel, V | 1 |
| McGurk, M | 1 |
| Karatay, E | 1 |
| Gül Utku, Ö | 1 |
| Erdal, H | 1 |
| Arhan, M | 1 |
| Önal, İK | 1 |
| Ibiş, M | 1 |
| Ekinci, Ö | 1 |
| Yilmaz Demirtaş, C | 1 |
| G Dumlu, Ş | 1 |
| Lyons, A | 1 |
| Ghazali, N | 1 |
| Hung, KY | 2 |
| Huang, JW | 2 |
| Chiang, CK | 1 |
| Tsai, TJ | 5 |
| Boerma, M | 1 |
| Roberto, KA | 1 |
| Hauer-Jensen, M | 1 |
| Ng, YY | 1 |
| Chen, YM | 3 |
| Lan, XR | 1 |
| Yang, WC | 1 |
| Lan, HY | 1 |
| Zhou, QG | 1 |
| Zheng, FL | 1 |
| Hou, FF | 1 |
| Mendes, JB | 1 |
| Campos, PP | 1 |
| Rocha, MA | 1 |
| Andrade, SP | 1 |
| Liu, H | 1 |
| Xiong, M | 1 |
| Xia, YF | 1 |
| Cui, NJ | 1 |
| Lu, RB | 1 |
| Deng, L | 1 |
| Lin, YH | 1 |
| Rong, TH | 1 |
| de Souza, RB | 1 |
| Macedo, AR | 1 |
| Kuruma, KA | 1 |
| Macedo, PA | 1 |
| Borges, CT | 1 |
| Peterson, TC | 2 |
| Peterson, MR | 1 |
| Raoul, JM | 1 |
| Szabolcsi, O | 1 |
| Nagy-Toldi, A | 1 |
| Zeher, M | 1 |
| Végh, J | 1 |
| Jacobson, G | 1 |
| Bhatia, S | 1 |
| Smith, BJ | 1 |
| Button, AM | 1 |
| Bodeker, K | 1 |
| Buatti, J | 1 |
| Gilbert-Sirieix, M | 1 |
| Lin, SL | 2 |
| Chien, CT | 1 |
| Chiang, WC | 2 |
| Tsai, CC | 1 |
| Cardoso, CC | 1 |
| Paviani, ER | 1 |
| Cruz, LA | 1 |
| Guma, FC | 1 |
| Borojevic, R | 1 |
| Guaragna, RM | 1 |
| Valente, EG | 1 |
| Vernet, D | 1 |
| Ferrini, MG | 1 |
| Qian, A | 1 |
| Rajfer, J | 2 |
| Gonzalez-Cadavid, NF | 1 |
| Okunieff, P | 1 |
| Augustine, E | 1 |
| Hicks, JE | 1 |
| Cornelison, TL | 1 |
| Altemus, RM | 1 |
| Naydich, BG | 1 |
| Ding, I | 1 |
| Huser, AK | 1 |
| Abraham, EH | 1 |
| Smith, JJ | 1 |
| Coleman, N | 1 |
| Gerber, LH | 1 |
| Georges, C | 1 |
| Lefaix, JL | 4 |
| Gothard, L | 1 |
| Cornes, P | 1 |
| Earl, J | 1 |
| Hall, E | 1 |
| MacLaren, J | 1 |
| Mortimer, P | 1 |
| Peacock, J | 1 |
| Peckitt, C | 1 |
| Woods, M | 1 |
| Yarnold, J | 1 |
| Chiao, TB | 1 |
| Lee, AJ | 1 |
| Chen, RH | 1 |
| Lai, CF | 1 |
| Wu, KD | 1 |
| Wang, Y | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Hsieh, BS | 1 |
| Gore, JL | 1 |
| Kaufman, J | 1 |
| Gonzalez-Cadavid, N | 1 |
| Gosselin, LE | 1 |
| Williams, JE | 1 |
| Bese, NS | 1 |
| Munzuroglu, F | 1 |
| Uslu, B | 1 |
| Arbak, S | 1 |
| Yesiladali, G | 1 |
| Sut, N | 1 |
| Altug, T | 1 |
| Ober, A | 1 |
| Gottlöber, P | 1 |
| Krähn, G | 1 |
| Korting, HC | 1 |
| Stock, W | 1 |
| Peter, RU | 1 |
| Neumeister, M | 1 |
| Futran, ND | 1 |
| Trotti, A | 1 |
| Gwede, C | 1 |
| Leplat, JJ | 1 |
| Tricaud, Y | 1 |
| Martin, M | 1 |
| Moser, M | 1 |
| Gong, Y | 1 |
| Johnson, J | 1 |
| Kneteman, N | 1 |
| Minuk, GY | 1 |
| Lédée-Bataille, N | 1 |
| Olivennes, F | 1 |
| Chaouat, G | 1 |
| Frydman, R | 1 |
| Bennett, WM | 1 |
| Elzinga, LW | 1 |
| Porter, GA | 1 |
| Rosen, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| Evaluation of the Medical Benefit of a Spa Therapy on the Evolutionary Genius of Late Sequelae Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission[NCT05874492] | 110 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | |||
| Double-Blind, Placebo-Controlled, Randomised Trial Of Alpha-Tocopherol And Oxpentifylline In Patients With Radiation Fibrosis[NCT00022204] | Phase 2 | 0 participants | Interventional | 2000-01-31 | Completed | ||
| Development of Radiation Fibrosis in Patients Treated With Pentoxyphylline and Vitamin E: a Prospective Randomized Study[NCT00583700] | Phase 2 | 54 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy[NCT00969111] | 70 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | |||
| An Expanded Phase II Study of Hypofractionated Dose Intense Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate[NCT01368055] | 361 participants (Actual) | Interventional | 2011-09-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A primary outcome of interest is the composite Subjective, Objective, Management, and Analytic (SOMA) score at 18-month follow-up visit. Maximum score is 45, with a score of 0 being ideal and representing no treatment-related side effects at the study visit. (NCT00583700)
Timeframe: 18 month post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Control Arm | 1.59 |
| Intervention: Pentoxifylline & Vitamin E | 1.0 |
"Tissue compliance meter measurements of the treated breast compared to the non-treated breast were obtained at 18 months post-radiation therapy. Tissue compliance simply means how soft and pliable the breast tissue is when force is applied to it.~One physician would hold the tissue compliance meter (TCM) against the participant's skin. A standard amount of force would be applied. A second physician would read the displacement scale for a specific set of areas on the breast. The range of the scale was 0 to 60 milimeters (mm). The physician's were blineded to the participant's intervention at the time of measurement.~The final value is the difference between the untreated and the treated breast [untreated - treated]. The range of these differences was -3.3 to 7.0 mm." (NCT00583700)
Timeframe: 18 months post-treatment
| Intervention | milimeters (mm) (Mean) |
|---|---|
| Control Arm | 2.10 |
| Intervention: Pentoxifylline & Vitamin E | 0.88 |
8 reviews available for pentoxifylline and Cirrhosis
| Article | Year |
|---|---|
Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Clinical Trials as Topic; Drug Repositioning; Fibro | 2017 |
Pentoxifylline and vitamin E for treatment or prevention of radiation-induced fibrosis in patients with breast cancer.
Topics: Breast Neoplasms; Female; Fibrosis; Humans; Pentoxifylline; Radiation Injuries; Radiation-Protective | 2018 |
The management of osteoradionecrosis of the jaws--a review.
Topics: Algorithms; Anti-Inflammatory Agents; Clodronic Acid; Fibrosis; Head and Neck Neoplasms; Humans; Hyp | 2015 |
Use of pentoxifylline and tocopherol in radiation-induced fibrosis and fibroatrophy.
Topics: Antioxidants; Atrophy; Fibrosis; Humans; Pentoxifylline; Radiation Injuries; Radiotherapy; Tocophero | 2017 |
Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis.
Topics: Antioxidants; Clinical Trials as Topic; Drug Therapy, Combination; Fibrosis; Humans; Pentoxifylline; | 2005 |
Peritoneal fibrosing syndrome: pathogenetic mechanism and current therapeutic strategies.
Topics: Dipyridamole; Fibrosis; Humans; Pentoxifylline; Peritoneal Dialysis; Peritoneum; Risk Factors; Syndr | 2005 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.
Topics: Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Hum | 2007 |
[The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report].
Topics: Breast Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Therapy, Combination; Fe | 1996 |
5 trials available for pentoxifylline and Cirrhosis
| Article | Year |
|---|---|
Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis.
Topics: Adult; Antioxidants; Drug Therapy, Combination; Female; Fibrosis; Humans; Male; Middle Aged; Pentoxi | 2009 |
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Compliance; Drug Therapy, Combination; Fem | 2013 |
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Compliance; Drug Therapy, Combination; Fem | 2013 |
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Compliance; Drug Therapy, Combination; Fem | 2013 |
Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Compliance; Drug Therapy, Combination; Fem | 2013 |
Pentoxifylline in the treatment of radiation-induced fibrosis.
Topics: Adolescent; Adult; Aged; Cytokines; Fibrosis; Humans; Middle Aged; Pentoxifylline; Radiation Injurie | 2004 |
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Confid | 2004 |
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Confid | 2004 |
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Confid | 2004 |
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chronic Disease; Combined Modality Therapy; Confid | 2004 |
Combined treatment by pentoxifylline and tocopherol for recipient women with a thin endometrium enrolled in an oocyte donation programme.
Topics: Adult; Birth Rate; Drug Therapy, Combination; Endometrium; Female; Fibrosis; Humans; Oocyte Donation | 2002 |
40 other studies available for pentoxifylline and Cirrhosis
| Article | Year |
|---|---|
Effects of Combination Treatments with Astaxanthin-Loaded Microparticles and Pentoxifylline on Intracellular ROS and Radiosensitivity of J774A.1 Macrophages.
Topics: Antioxidants; Cells, Cultured; Fibrosis; Humans; Macrophages; Microplastics; Oxidative Stress; Pento | 2021 |
The Preventive Effect of Systemic Honokiol and Systemic Pentoxifylline on Epidural Fibrosis.
Topics: Animals; Biphenyl Compounds; Epidural Space; Fibrosis; Laminectomy; Lignans; Pentoxifylline; Rats | 2021 |
Pentoxifylline-induced protein expression change in RAW 264.7 cells as determined by immunoprecipitation-based high performance liquid chromatography.
Topics: Animals; Chromatography, High Pressure Liquid; Fibrosis; Immunoprecipitation; Inflammation; Mice; NF | 2022 |
Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy.
Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Disease Models, Animal; Fibrosis; Gene Expression Pr | 2023 |
Effects of pentoxifylline and tocopherol on a rat-irradiated jaw model using micro-CT cortical bone analysis.
Topics: Animals; Antioxidants; Bone Diseases, Metabolic; Cortical Bone; Fibrosis; Male; Mandible; Osteoradio | 2019 |
Comparison of the effects of pentoxifylline, simvastatin, tamoxifen, and losartan on cavernous bodies after penile fracture in rats: a stereological study.
Topics: Animals; Fibrosis; Losartan; Male; Penile Diseases; Pentoxifylline; Rats; Simvastatin; Tamoxifen | 2020 |
Development and Characterization of an In Vitro Model for Radiation-Induced Fibrosis.
Topics: Cell Movement; Cell Proliferation; Collagen; Curcumin; Extracellular Matrix; Fibroblasts; Fibrosis; | 2018 |
Comparing the antifibrotic effect on the liver of Telmisartan and Pentoxifylline, in a Wistar rat experimental model.
Topics: Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Fibrosis; Liver; Models, Theoretical; Pe | 2017 |
The Akt/FoxO/p27
Topics: Animals; Cell Cycle Checkpoints; Cell Proliferation; Cicatrix, Hypertrophic; Cyclin-Dependent Kinase | 2019 |
MiR-210: A potential therapeutic target against radiation-induced enteropathy.
Topics: alpha-Tocopherol; Antioxidants; Cells, Cultured; Drug Therapy, Combination; Fibrosis; Humans; Hypoxi | 2014 |
Hepatoprotective effects of early pentoxifylline administration on hepatic injury induced by concanavalin A in rat.
Topics: Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Chemical and Drug Induced Liv | 2014 |
Orbital immunoglobulin IgG4-related inflammatory fibrosclerosing lesion treated with pentoxifylline and α-tocopherol: case report.
Topics: Adult; alpha-Tocopherol; Anti-Inflammatory Agents; Antioxidants; Autoimmune Diseases; B-Lymphocytes; | 2015 |
Pentoxifylline Ameliorates Cardiac Fibrosis, Pathological Hypertrophy, and Cardiac Dysfunction in Angiotensin II-induced Hypertensive Rats.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Hypertension; Inflammation Mediators; Male; Pentoxi | 2016 |
Pentoxifylline Inhibits Epidural Fibrosis in Post-Laminectomy Rats.
Topics: Animals; Epidural Space; Fibroblasts; Fibrosis; Hydroxyproline; Laminectomy; Male; Pentoxifylline; P | 2016 |
Pentoxifylline attenuates mucosal damage in an experimental model of rat colitis by modulating tissue biomarkers of inflammation, oxidative stress, and fibrosis.
Topics: Animals; Biomarkers; Colitis; Disease Models, Animal; Female; Fibrosis; Inflammation; Intestinal Muc | 2017 |
Osteoradionecrosis of the jaws: current understanding of its pathophysiology and treatment.
Topics: Animals; Antioxidants; Cranial Irradiation; Cytokines; Drug Combinations; Drug Synergism; Fibrosis; | 2008 |
Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies.
Topics: Animals; Base Sequence; Cells, Cultured; Collagen Type I; Cytokines; Dialysis Solutions; Disease Mod | 2008 |
Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol.
Topics: alpha-Tocopherol; Animals; Cell Count; Collagen Type I; Collagen Type III; Cytoskeleton; Diastole; F | 2008 |
Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats.
Topics: Animals; Disease Models, Animal; Fibrosis; Glomerulonephritis; Kidney; Male; Models, Biological; Pen | 2009 |
Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Female; Fibrosis; Humans; Hypoxia-Inducible Factor | 2009 |
Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice.
Topics: Animals; Cilostazol; Disease Models, Animal; Fibrosis; Inflammation; Male; Mice; Mice, Inbred BALB C | 2009 |
Studies on pentoxifylline and tocopherol combination for radiation-induced heart disease in rats.
Topics: Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fibrosis; Heart; Heart Diseases; M | 2009 |
The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis.
Topics: Animals; Colitis; Collagen Type I; Colon; Disease Models, Animal; Female; Fibrosis; Inflammation; In | 2011 |
[Systemic sclerosis in a patient suffering from breast cancer].
Topics: Adult; Amlodipine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Duct | 2012 |
Radiation-induced enteropathy: molecular basis of pentoxifylline-vitamin E anti-fibrotic effect involved TGF-β1 cascade inhibition.
Topics: Adult; Aged; Algorithms; Antioxidants; Blotting, Western; Clinical Trials as Topic; Enzyme-Linked Im | 2012 |
Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cell Division; Cells, Cultured; C | 2002 |
Effect of pentoxifylline on arachidonic acid metabolism, neutral lipid synthesis and accumulation during induction of the lipocyte phenotype by retinol in murine hepatic stellate cell.
Topics: Adipocytes; Animals; Arachidonic Acid; Azo Compounds; Cell Cycle; Cell Division; Cell Line; Cell Mem | 2003 |
L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
Topics: Animals; Apoptosis; Arginine; Blotting, Western; Cyclic GMP; Enzyme Inhibitors; Fibrosis; Humans; Ma | 2003 |
Case report: resolution of symptomatic epidural fibrosis following treatment with combined pentoxifylline-tocopherol.
Topics: Adult; Antioxidants; Chronic Disease; Drug Therapy, Combination; Fibrosis; Humans; Intervertebral Di | 2004 |
Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor.
Topics: Actins; Angiotensin II; Animals; Cell Line; Collagen Type I; Connective Tissue Growth Factor; Fibros | 2005 |
Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
Topics: Animals; Blood Pressure; Body Weight; Cell Proliferation; Cyclic GMP; Drinking; Fibrosis; Glomerulon | 2006 |
Case report: Avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide.
Topics: Arginine; Enzyme Inhibitors; Fibrosis; Humans; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthas | 2006 |
Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle.
Topics: Animals; Collagen Type I; Collagen Type III; Diaphragm; Disease Models, Animal; Enzyme Inhibitors; F | 2006 |
Vitamin E protects against the development of radiation-induced pulmonary fibrosis in rats.
Topics: Animals; Antioxidants; Dietary Supplements; Drug Therapy, Combination; Female; Fibrosis; Free Radica | 2007 |
Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in its mechanism.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Bile Ducts; Cell Division; Collagen; Dis | 1996 |
Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations.
Topics: Administration, Oral; Aged; Analgesics; Anti-Bacterial Agents; Atrophy; Debridement; Dose-Response R | 1997 |
Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol.
Topics: Aged; Drug Therapy, Combination; Female; Fibrosis; Humans; Pentoxifylline; Radiation Injuries; Radio | 1998 |
Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study.
Topics: Drug Combinations; Fibrosis; Gamma Rays; Humans; Muscle, Skeletal; Pentoxifylline; Radiation Injurie | 1999 |
Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study.
Topics: Drug Combinations; Fibrosis; Gamma Rays; Humans; Muscle, Skeletal; Pentoxifylline; Radiation Injurie | 1999 |
Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study.
Topics: Drug Combinations; Fibrosis; Gamma Rays; Humans; Muscle, Skeletal; Pentoxifylline; Radiation Injurie | 1999 |
Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study.
Topics: Drug Combinations; Fibrosis; Gamma Rays; Humans; Muscle, Skeletal; Pentoxifylline; Radiation Injurie | 1999 |
Effect of preoperative interventions on outcome following liver resection in a rat model of cirrhosis.
Topics: Animals; Anti-Infective Agents; Aspartate Aminotransferases; Bilirubin; Ciprofloxacin; Diagnosis, Co | 2000 |
The effects of pentoxifylline on experimental chronic cyclosporine nephrotoxicity.
Topics: Animals; Cyclosporine; Fibrosis; Kidney; Kidney Diseases; Male; Pentoxifylline; Rats; Rats, Sprague- | 1992 |